EDRN Biomarker Reference Lab: Pacific Northwest National Laboratory

Abbreviated Name
BRL: PNNL
Lead Investigator
Liu, TaoPacific Northwest National Laboratory
Coordinating Investigator
No coordinating investigator
Involved Investigators

Abstact

Aims

Stage I: A feasibility study – comparing a limited number (5) of available scFv library derived antibodies (in a number of antibody formats such as scFv, Fab and IgG) and commercially available monoclonal antibodies directed at the same cancer-associated antigens on the same slide with appropriate controls. This will involve identification, development, and production, of 20 monoclonal antibody pairs specific for 5 antigens with subsequent utilization demonstrated in a micro ELISA assay. The antibody pairs are represented by one detection antibody and 4 capture antibodies derived as affinity matured subclones directed against the same epitope. The capture antibodies will have affinities ranging from 100 nM to 100 pM. Stage II: Extension of the phase I study to ~50 antigens and controls chosen on the basis of potential as cancer biomarkers. In this stage PNNL will: (a) train selected EDRN investigators in the use of the microarray platform, and (b) print a large number of microarrays (1500 slides) for analytical and clinical validation studies.

Analytic Method

Biomarkers

  • No biomarkers available at this time for this protocol

Data Collections

  • No data available at this time for this protocol
 Team Project
Protocol ID
231
Protocol Type
Single
Field of Research
Other, Specify
Collaborative Group
(No collaborative group)
Cancer Types
  • (No cancer types specified)

Associated Forms